Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectivesReport as inadecuate




Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 5:147

First Online: 15 November 2005Received: 17 December 2004Accepted: 15 November 2005DOI: 10.1186-1471-2407-5-147

Cite this article as: Durando, X., Thivat, E., D-Incan, M. et al. BMC Cancer 2005 5: 147. doi:10.1186-1471-2407-5-147

Abstract

BackgroundMedian survival of metastatic malignant melanoma is 6.0 to 7.5 months, with a 5-year survival of ~6.0%. Although long-term complete remissions are rare, few reports describe cases after chemotherapy. Fifty-three patients with metastatic melanoma were treated with Cystemustine, a chloroethyl nitrosourea CENU 60 or 90 mg-m.

Case presentationWe describe 5 cases, presenting with complete response with long-term disease-free survival of long-term remission of 14, 12, 9, 7 and 6 years after Cystemustine therapy alone.

ConclusionLong-term survival has already been described in literature, but in all cases they have been obtained after chemotherapy associated with or followed by surgery. But despite these noteworthy and encouraging but also rare results, it appears essential to increase cystemustine efficiency.

Download fulltext PDF



Author: Xavier Durando - Emilie Thivat - Michel D-Incan - Anne Sinsard - Jean-Claude Madelmont - Philippe Chollet

Source: https://link.springer.com/







Related documents